retatrutide clinical trial results 2025 Eli Lilly infiltrates anti-obesity market as Phase III for begins Lilly's triple agonist, retatrutide, delivered

(GLP3 Planner) If ongoing trials continue to show favorable results, regulatory approval could potentially occur around 20272028, depending on final data and review timelines

Link Christou, G

The simplest way to picture it is by counting receptors: semaglutide targets one hormone pathway, tirzepatide targets two, and retatrutide targets three

Have you ever thought about GLP-1 for weight loss

A phase 3 programme evaluating retatrutide across multiple populations including adults with obesity, adults with type 2 diabetes, and individuals with obesity-related comorbidities is under way

These medications imitate the actions of the endogenous hormone GLP-1, prompting activation of its receptor, which then sets off multiple positive metabolic responses